Fragile X Syndrome clinical trials at UC Davis
2 research studies open to eligible people
Metformin in Individuals With Fragile X Syndrome
“Learn if Metformin may be helpful for language, behavior problems, and obesity / excessive appetite in patients with Fragile X Syndrome.”
open to eligible people ages 6-25
This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either drug or placebo and will attend three visits to the study site in a 4-month period for a series of tests. The primary objectives are to assess safety, tolerability, and efficacy of metformin in the treatment of language deficits, behavior problems, and obesity/excessive appetite in individuals with fragile X syndrome.
Sacramento, California and other locations
Cannabidiol in Children, Adolescents, and Young Adults with Fragile X Syndrome
“Children and teens between 3 and 17 diagnosed with Fragile X syndrome may qualify for a clinical trial”
open to eligible people ages 3-29
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to < 30 years will be eligible to participate.
Sacramento, California and other locations
Our lead scientists for Fragile X Syndrome research studies include Randi J Hagerman, MD.